1. Home
  2. CLDX vs FSK Comparison

CLDX vs FSK Comparison

Compare CLDX & FSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celldex Therapeutics Inc.

CLDX

Celldex Therapeutics Inc.

N/A

Current Price

$28.86

Market Cap

3.0B

Sector

Health Care

ML Signal

N/A

Logo FS KKR Capital Corp.

FSK

FS KKR Capital Corp.

N/A

Current Price

$11.68

Market Cap

3.0B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CLDX
FSK
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.0B
IPO Year
1995
2008

Fundamental Metrics

Financial Performance
Metric
CLDX
FSK
Price
$28.86
$11.68
Analyst Decision
Strong Buy
Hold
Analyst Count
15
11
Target Price
★ $64.00
$12.13
AVG Volume (30 Days)
899.2K
★ 2.3M
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
★ 17.57%
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $12,743,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$75.84
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 87.78
N/A
52 Week Low
$22.33
$9.72
52 Week High
$45.14
$16.31

Technical Indicators

Market Signals
Indicator
CLDX
FSK
Relative Strength Index (RSI) 43.45 59.32
Support Level $28.26 $10.10
Resistance Level $31.83 $11.73
Average True Range (ATR) 1.44 0.35
MACD 0.15 0.10
Stochastic Oscillator 26.35 57.21

Price Performance

Historical Comparison
CLDX
FSK

About CLDX Celldex Therapeutics Inc.

Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

About FSK FS KKR Capital Corp.

FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.

Share on Social Networks: